Incidence and Mortality of Obstructive Lung Disease in Rheumatoid Arthritis: A Population-Based Study




Pulmonary disease represents an important extraarticular manifestation of rheumatoid arthritis (RA). While the association of RA and interstitial lung disease is widely acknowledged, obstructive lung disease (OLD) in RA is less well understood. We therefore aimed to assess the incidence, risk factors, and mortality of OLD in patients with RA.


We examined a population-based incident cohort of patients with RA and a comparison cohort of individuals without RA. OLD was defined using a strict composite criterion. Cox proportional hazards models were used to compare OLD incidence between the RA and comparator cohorts to investigate risk factors and to explore the impact of OLD on patient survival.


A total of 594 patients with RA and 596 subjects without RA were followed for a mean of 16.3 and 19.4 years, respectively. The lifetime risk of developing OLD was 9.6% for RA patients and 6.2% for subjects without RA (hazard ratio [HR] 1.54, 95% confidence interval [95% CI] 1.01–2.34). The risk of developing OLD was higher among male patients, among current or former smokers, and for individuals with more severe RA. Survival of RA patients diagnosed with OLD was worse compared to those without OLD (HR 2.09, 95% CI 1.47–2.97).


Patients with RA are at higher risk of developing OLD, which is significantly associated with premature mortality. Effective diagnostic and therapeutic strategies to detect and manage OLD in patients with RA may help to improve survival in these patients.


While the association of interstitial lung disease (ILD) and rheumatoid arthritis (RA) is widely acknowledged, the risk and impact of obstructive lung disease (OLD) in patients with RA is less clear. Studies exploring this potential association have so far relied on the prevalence of pulmonary obstruction in consecutive samples, focusing on differences in pulmonary function testing and computed tomography (CT) morphology between patients with RA and comparator subjects. To date, no study has been performed evaluating the incidence of OLD in a population-based cohort.

A wide variety of pulmonary disorders can result in airway obstruction, with chronic obstructive pulmonary disease (COPD) and asthma as the two most common forms of OLD in the general population. Importantly, clinical symptoms of airway obstruction as well as an obstructive pattern on pulmonary function testing can also occur with bronchiolar involvement in ILD (constrictive or follicular bronchiolitis) and large airway disease (bronchiectasis). Case series have suggested that bronchiectasis and constrictive bronchiolitis may represent distinct extraarticular manifestations of RA ([1]). However, estimates based on patients with RA who are seen in academic centers carry the inherent risk of overestimating various clinical end points, since extraarticular manifestations of RA are more frequently found in patients with more severe disease ([2]). In light of the significant mortality risk associated with extraarticular disease in RA ([3]), a clear definition of the individual subtypes of RA-associated comorbidities would be an essential step toward improving patient care. We therefore aimed to investigate the incidence, risk factors, and mortality of OLD in patients with RA in a population-based setting.

Box 1. Significance & Innovations

  • Obstructive lung disease is more common in patients with rheumatoid arthritis (RA) compared to individuals without RA.
  • Obstructive lung disease does contribute to the excess mortality in patients with RA.


The population of Rochester, Minnesota is well suited for investigation of long-term outcomes of patients with RA. A medical records linkage system, the Rochester Epidemiology Project, allows ready access to the complete records from all health care providers for the local population. The potential of this data system for population-based research has been previously described ([4]). This system ensures virtually complete clinical and vital status information on all clinically recognized cases of RA among Rochester residents.

Cohort of patients with RA.

A population-based incidence cohort of all cases of RA first diagnosed between January 1, 1955 and January 1, 1994 among Rochester, Minnesota residents ages ≥18 years was assembled as previously described ([5-7]). All cases fulfilled the 1987 American College of Rheumatology (ACR) classification criteria for RA ([8]). Incidence date was defined as the first date of fulfillment of 4 of the 7 ACR criteria. This RA incidence cohort consists of 603 subjects.

Comparison cohort of patients without RA.

For each of the 603 subjects with RA, an individual without RA with a similar birth year (±3 years) and same sex was randomly selected from the same source population. Each subject in this cohort was assigned an index date corresponding to the RA incidence date of the corresponding patient with RA.

Data collection.

The data abstraction process has been described in detail ([5-7]). Briefly, all subjects were followed up longitudinally through their complete medical records beginning at age 18 years and continuing until death, migration from Rochester, or January 1, 2006. Comorbidities were abstracted as previously described ([9]).

Classification of OLD.

The criteria used for classification of OLD were based on consensus-forming discussions between 2 rheumatologists (TB, ELM) and 2 pulmonologists (JHR, RV). OLD was defined as the presence of airflow obstruction based on ≥1 spirometry result with a forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio <0.7, consistent with the American Thoracic Society/European Respiratory Society diagnostic criteria ([10]). In addition, patients classified as having OLD needed ≥1 documented physician diagnosis of airway or parenchymal lung disease such as COPD (including emphysema and/or chronic bronchitis), asthma, ILD, bronchiolitis, or bronchiectasis. The medical records of all 1,206 subjects were reviewed and pulmonary diagnoses, spirometry results, and chest radiographic data were abstracted into number/identifier codes. Of note, final classification of a patient as having OLD was made after completion of the chart review. We applied a computer-based algorithm to the pulmonary function testing results and pulmonary diagnoses were abstracted for every study subject, e.g., if an FEV1/FVC ratio <0.7 and a physician diagnosis of airway/parenchymal pulmonary disease were present, the study subject was classified as having OLD. For every subject with OLD, we applied additional criteria for subclassification (Table 1).

Table 1. OLD (FEV1/forced vital capacity <0.7): definition of subtypes*
OLD subtypeCriterion
  1. OLD = obstructive lung disease; FEV1 = forced expiratory volume in 1 second; COPD = chronic obstructive pulmonary disease; CT = computed tomography; ILD = interstitial lung disease; TLC = total lung capacity.
COPDPhysician's diagnosis of COPD (chronic bronchitis or emphysema)
 OR chest radiograph or CT: diagnosis of emphysema
 OR airflow obstruction with <20% improvement of FEV1 with bronchodilator and no alternative explanation for the patient's respiratory symptoms
AsthmaPhysician's diagnosis of asthma
 AND ≥20% improvement of FEV1 with bronchodilator
BronchiectasisDiagnosis of bronchiectasis by a pulmonologist based on clinical and radiologic data
 OR chest radiograph or CT: diagnosis of bronchiectasis according to radiologist
Obstructive bronchiolar disordersDiagnosis of bronchiolitis obliterans (or obliterative/constrictive bronchiolitis) by pulmonologist
 OR CT diagnosis of bronchiolitis obliterans (or obliterative/constrictive bronchiolitis) by radiologist
ILD-associated airflow obstructionPhysician's diagnosis of ILD
 PLUS CT/chest radiograph consistent with ILD and/or 1 of the following criteria:
 TLC ≤80% of predicted
 Bronchoscopic or surgical lung biopsy results consistent with ILD

Cause of death.

For all patients diagnosed with OLD who died during the followup period, we determined the cause of death using death certificate data and hospitalization records. In the case of discrepancy between the death certificate diagnosis and physician notes/hospitalization records, the cause of death was determined by one of the physician reviewers (TB) based on chart review.

Statistical analysis.

Descriptive statistics were used to summarize the data. Demographics were compared using 2-sample t-tests and chi-square tests. Cumulative incidence of OLD was estimated, adjusting for the competing risks of death. Cox proportional hazards models were used to compare the incidence of OLD in patients with RA versus individuals without RA and to investigate possible associations of demographic and clinical variables with OLD. Time-dependent covariates were used to represent risk factors that could develop over time. Kaplan-Meier methods were used to estimate survival. Cox proportional hazards models were used to compare the mortality in patients with RA and OLD to patients with OLD who did not have RA and to compare survival of patients with RA and OLD to patients with RA who did not develop OLD. In this case, OLD was modeled using a time-dependent covariate to account for the development of OLD during followup. Cox proportional hazards models were also used to evaluate the impact of risk factors on mortality following OLD in RA patients. Finally, we estimated the risk of mortality attributable to OLD in the RA cohort. Attributable risk is commonly calculated according to the equation AR = (P[D] − P[D, no F])/P(D), where AR = the attributable risk, P(D) = the probability of disease (i.e., death), and P(D, no F) = the conditional probability of disease among individuals without the risk factor. The cumulative incidence of death was used to estimate the probability of death, and these estimates were obtained from Cox models to allow for adjustment for age and sex. The conditional probability of death for those without OLD was estimated from the same Cox models, but with a target cohort that matched the observed cohort except for the fact that the subjects did not have OLD. The analyses were performed using SAS, version 9, and Splus (Insightful) software.


Study subjects.

The population-based cohort of patients with RA and the comparison cohort comprised 603 patients each. After exclusion of 9 patients with RA and 7 without RA who developed OLD prior to the RA incidence/index date, 594 patients with incident RA and 596 comparison subjects were used for analysis. The mean age at RA incidence/index date was 58 years. The mean duration of followup was 16.3 years for RA patients and 19.4 years for subjects without RA. Seventy-three percent of the patients were women. Smoking was more common among RA patients: 28.5% of RA patients were current smokers and 23.6% were former smokers compared to 23.8% current smokers and 19.6% former smokers in the non-RA comparator group (P < 0.01). The number of individuals who did undergo pulmonary function testing or chest imaging at any point during followup was similar between RA and non-RA subjects. There were also no statistically significant differences among patients with and without RA regarding alcohol consumption, diabetes mellitus, obesity, and coronary heart disease (Table 2).

Table 2. Demographic and clinical characteristics*
 Patients with RA (n = 594)Subjects without RA (n = 596)P
  1. Values are the number (percentage) unless otherwise indicated. Percentages are based on available data. RA = rheumatoid arthritis.
  2. aMultigroup comparison: never vs. current vs. former smoker.
  3. bEver performed until last date of followup.
  4. cIncludes angina pectoris, coronary artery disease, coronary insufficiency, ischemic heart disease, myocardial infarction, heart failure, pulmonary edema, and coronary revascularization procedures.
Age at RA diagnosis/index date, mean ± SD years57.8 ± 15.258.1 ± 15.30.71
Followup, mean ± SD years16.3 ± 10.519.4 ± 11.1
Women435 (73.2)438 (73.5)0.92
Smoking status  0.01a
Current smoker169 (28.5)142 (23.8) 
Former smoker140 (23.6)117 (19.6) 
Pulmonary function availableb114 (19.2)97 (16.3)0.18
Chest radiograph availableb585 (98.5)582 (97.7)0.30
Baseline12 (2.0)17 (3.0)0.28
Ever41 (6.9)26 (4.6)
Diabetes mellitus   
Baseline43 (7.2)40 (6.7)0.72
Ever111 (18.7)143 (24.0)
Baseline71 (12.0)65 (11.0)0.75
Ever136 (22.9)140 (23.5)
Heart diseasec   
Baseline76 (12.8)72 (12.1)0.71
Ever281 (47.3)233 (39.1)

Incidence of OLD in patients with RA.

During followup, 52 RA patients and 40 subjects without RA met the OLD classification criterion. The 10-, 20-, and 30-year cumulative incidence rates for OLD (adjusted for the competing risk of death) were 3.7%, 6.9%, and 9.6%, respectively. Among comparison subjects, the 10-, 20-, and 30-year cumulative incidence rates were 2.6%, 5.2%, and 6.2%, respectively (Figure 1). The risk of developing OLD in patients with RA was significantly higher than in subjects without RA (hazard ratio [HR] 1.54, 95% confidence interval [95% CI] 1.01–2.34 after adjusting for age, sex, smoking, and alcoholism). The risk of developing OLD in patients with RA who never smoked was higher than in subjects without RA who never smoked, but this difference did not reach statistical significance (HR 1.98, 95% CI 0.73–5.40 after adjusting for age and sex).

Figure 1.

Incidence of obstructive lung disease in patients with rheumatoid arthritis (RA; solid line) and subjects without RA (broken line).

Subtypes of OLD in patients with and without RA.

COPD was the most common subtype in subjects with OLD. COPD and ILD were much more common in patients with RA compared to subjects in the non-RA cohort. Conversely, asthma was diagnosed more frequently among subjects without RA than in patients with RA. A detailed depiction of OLD subtypes is shown in Table 3.

Table 3. Types of lung disease (including overlap of 2 different pathologies) underlying airway obstruction in RA and non-RA patients*
Type of lung diseaseRA cohortNon-RA cohort
  1. RA = rheumatoid arthritis; COPD = chronic obstructive pulmonary disease; ILD = interstitial lung disease.
COPD + asthma14
COPD + bronchiectasis11
ILD + bronchiectasis1 (traction bronchiectasis)0

Although the low number of patients with pulmonary disease who never smoked precluded any meaningful statistical analysis, we stratified OLD subtypes by “never” versus “ever” smoking status: among the 9 RA patients with OLD who never smoked, 5 were diagnosed with COPD, 3 were diagnosed with bronchiectasis, and 1 subject was affected by asthma. Conversely, the most common diagnosis among the 7 non-RA subjects who never smoked was asthma (5 individuals), followed by asthma/COPD overlap and bronchiectasis in 1 patient each.

Demographic and clinical characteristics of subjects with OLD.

Patients with RA were younger at the time of OLD diagnosis compared with subjects without RA. The characteristics of OLD in RA and non-RA patients are shown in Table 4. Abnormalities detected with chest imaging were more frequent in the RA group compared with the non-RA patients. The minimum FEV1 had a lower mean ± SD value among the patients with RA (1.30 ± 0.73 liters) compared to subjects without RA (1.45 ± 0.56 liters), indicating more severe obstruction in patients with RA. However, this difference was not statistically significant.

Table 4. Characteristics of OLD in patients with RA and non-RA patients*
 RA (n = 52)Non-RA (n = 40)
  1. Values are the number (percentage) unless otherwise indicated. OLD = obstructive lung disease; RA = rheumatoid arthritis; CT = computer tomography; FEV1 = forced expiratory volume in 1 second.
Age at RA diagnosis, mean ± SD years54.0 ± 13.257.5 ± 14.1
Age at OLD diagnosis, mean ± SD years69.2 ± 12.974.4 ± 10.4
Men23 (44.2)16 (40.0)
Current smoker31 (59.6)21 (52.5)
Former smoker12 (23.1)12 (30.0)
Abnormal radiograph or CT (at any time)  
Emphysema27 (51.9)14 (35.0)
Bronchiectasis5 (9.6)1 (2.5)
Interstitial lung disease7 (13.5)1 (2.5)
Minimum FEV1 (at any time), liters  
Mean ± SD1.30 ± 0.731.45 ± 0.56
0.37 to <0.8417 (32.7)6 (15.0)
0.84 to <1.2913 (25.0)10 (25.0)
1.29 to <1.8511 (21.2)12 (30.0)
1.85 to <3.4111 (21.2)12 (30.0)

Risk factors for OLD in patients with RA.

The incidence of RA-associated OLD was higher in men (HR 2.43, 95% CI 1.40–4.21) and among RA patients who were active or past smokers (HR 4.38, 95% CI 2.14–8.99) (Table 5). Other risk factors that had a statistically significant association with OLD were related to disease severity, including rheumatoid factor, elevated erythrocyte sedimentation rate (ESR), and corticosteroid and disease-modifying antirheumatic drug (DMARD) use. Other features of disease severity (extraarticular disease, large joint swelling, and decreased functional status) all had HRs >1.5, albeit not statistically significant (Table 5).

Table 5. Risk factors for OLD in patients with RA*
 RA patients without OLD (n = 542)RA patients with OLD (n = 52)HR (95% CI)a
  1. Values are the number (percentage) unless otherwise indicated. Percentages are based on available data. OLD = obstructive lung disease; RA = rheumatoid arthritis; HR = hazard ratio; 95% CI = 95% confidence interval; ESR = erythrocyte sedimentation rate; DMARD = disease-modifying antirheumatic drug.
  2. aModels in rows 4–15 are adjusted for age at RA diagnosis, sex, and ever smoker.
  3. bSignificant.
  4. cIncludes Felty's syndrome, pleuritis, pericarditis, rheumatoid myocarditis, and rheumatoid vasculitis.
  5. dAccording to the Steinbrocker index.
  6. e3 + 4 vs. 1 + 2.
Age at RA diagnosis (per 10-year increase), mean ± SD years58.2 ± 15.454.0 ± 13.21.20 (0.96–1.48)
Sex (male)136 (25.1)23 (44.2)2.43 (1.40–4.21)
Smoking (ever)266 (49.1)43 (82.7)4.38 (2.14–8.99)b
Extraarticular disease (ever)c84 (15.5)8 (15.4)1.84 (0.86–3.95)
Rheumatoid factor (ever)341 (66.3)42 (82.4)2.93 (1.41–6.10)b
Joint erosions on radiographs (ever)85 (17.7)6 (12.2)0.76 (0.32–1.81)
Erosions or destructive changes (ever)273 (57.0)26 (53.1)0.95 (0.53–1.70)
ESR: 3 values ≥60 mm/hour (ever)157 (29.0)15 (28.8)1.86 (1.01–3.43)b
Large joint swelling (ever)450 (83.0)46 (88.5)2.13 (0.90–5.07)
Rheumatoid nodules (ever)169 (31.2)17 (32.7)1.36 (0.75–2.45)
DMARD use (ever)303 (55.9)34 (65.4)2.01 (1.10–3.64)b
Methotrexate use (ever)121 (22.3)10 (19.2)1.18 (0.58–2.41)
Steroid use (ever)281 (51.8)31 (59.6)2.50 (1.43–4.40)b
Functional capacity = 1 + 2d431 (80.1)37 (74.0)1.71 (0.90–3.24)e
Functional capacity = 3 + 4d107 (19.9)13 (26.0) 

Association of mortality with OLD in patients with RA.

Kaplan-Meier estimates of survival following diagnosis of OLD were similar for RA patients and non-RA subjects. The 5-year survival rate was 59% among RA patients and 64% among non-RA subjects. The difference in mortality risk between patients with RA and OLD and subjects without RA and OLD was not statistically significant after adjustment for age, sex, smoking status, and alcoholism (HR 1.81, 95% CI 1.00–3.28; P = 0.052).

We also compared the survival experience of RA patients with OLD to RA patients who did not develop OLD. The development of OLD among patients with RA was significantly associated with worse survival compared to RA patients without OLD after adjustment for age, sex, smoking status, and alcoholism (HR 2.09, 95% CI 1.47–2.97).

Among RA patients with OLD, a higher mortality risk was significantly associated with age at OLD onset (per 10-year increase in age: increase in HR 1.94, 95% CI 1.32–2.84) and a low functional capacity (level 3 and 4 versus level 1 and 2, adjusted for age, sex, and smoking status: HR 3.16, 95% CI 1.43–6.99).

Death diagnoses.

Among the 52 patients with RA and OLD, 21 (40.4%) died of pulmonary causes. “Respiratory failure secondary to COPD” was the most common death diagnosis in 12 of these patients, followed by “respiratory infection (pneumonia)” in 7 individuals and cor pulmonale and pneumothorax in 1 patient each.

Conversely, only 5 subjects (12.5%) among the 40 subjects in the control cohort died of pulmonary causes. “Respiratory failure secondary to COPD” was the death diagnosis in 3 subjects, while 2 patients succumbed to metastatic lung cancer.

Excess mortality of patients with RA attributable to OLD.

The cumulative incidence of death was 71.8% in patients with RA at 30 years after the RA incidence date, compared to 60.2% in patients without RA. Based on this, the RA cohort has an excess mortality of 12.6% at 30 years after RA incidence.

When reducing the rate of OLD in RA patients to the rate of OLD in the non-RA cohort, the cumulative mortality of RA patients dropped by 0.8%. Therefore, the excess deaths in RA would be reduced by 6.3% (0.8%/12.6%) if the risk of OLD in RA patients was the same as in non-RA subjects.


The results of our population-based study indicate an increased risk for OLD in patients with RA. Furthermore, we provide evidence that airway obstruction is associated with the higher mortality of patients with RA.

Our population-based approach does offer the advantage of a comprehensive assessment of all patients diagnosed with RA in a defined geographic area, thereby minimizing the risk of referral bias. We utilized an acknowledged, objective criterion for pulmonary obstruction based on pulmonary function testing in order to avoid misclassification that can occur when relying on International Classification of Diseases codes or claims data ([11]).

Although we were unable to identify previously published data on the incidence of OLD in RA, several studies have explored the prevalence of OLD among RA patients in consecutive samples or claims-based databases. In a 1979 study ([12]), the prevalence of “airways obstruction” in patients with RA was 24% versus 3% in control subjects, which is more than twice as high as the 30-year cumulative incidence in our study. In that study, the definition of airway obstruction differed significantly from our classification criterion: a FEV1/FVC ratio <84% of predicted was used as a criterion for the presence of disease. An even higher prevalence of OLD in patients with RA was reported by other authors who found that 18 (41%) of 43 patients with RA had an FEV1/FVC <0.7 ([13]). Several distinctive features of this cohort have to be taken into account: 77% of subjects were smokers, patients had very severe RA requiring hospitalization (mean “total joint count” 34, mean ESR 40 mm/hour), and an unusually high proportion of male study subjects was present (50%). Such a cohort is unlikely to be representative of the full spectrum of RA in the population.

In a more recent study, 100 patients with RA were investigated for OLD ([14]). The diagnosis of respiratory disorders was based on clinical, radiologic, and spirometry findings. OLD affected 11% of patients with RA. Although the estimate is much closer to our 30-year cumulative incidence, the complete absence of any OLD in the control cohort of this trial appears unusual, given that approximately 10% of the US population has COPD ([15]). In general, the differing estimates of OLD in patients with RA among studies have to be interpreted in the context of variable disease definitions, different study populations, and the varying extent of pulmonary function and imaging-based testing applied.

What could be the explanation for the observed association of RA and OLD? Considering the role of smoking as an important risk factor for both RA and COPD, it appears possible that the observed association between RA and OLD is noncausal and merely the result of confounding. This could even be the case when adjusting for crude categories such as never smoker, current smoker, and previous smoker, since this categorization would not take into account the individual “dose” of smoking. Because smoking is a risk factor for RA ([16]), it is possible that cohorts of RA patients could include heavier smokers than persons without RA of a similar age and same sex, thereby also increasing the likelihood of COPD in these patients. Adjusting for broad categories of smoking behavior would not adjust for this difference. However, when limiting our analysis to nonsmokers, pulmonary obstruction was still twice as likely among RA patients when compared to non-RA subjects (although the low number of nonsmokers did not allow a statistically meaningful analysis), providing evidence in favor of a true casual association.

Based on what is currently known, the risk genes identified for RA and COPD do not appear to overlap. Although many of the risk genes for COPD are positioned in pathways of oxidative stress response ([17]), RA risk genes are pointing toward pathways of T cell activation and antigen presentation ([18]). Therefore, there is currently no evidence that the observed association would be due to common risk genes that are shared between both diseases. It has been speculated that pulmonary injury may predispose patients to development of RA ([19, 20]). However, a recent population-based study did not reveal a higher risk of RA in patients with established COPD ([21]).

The 3 subtypes of OLD that were more frequently observed in patients with RA as compared to non-RA subjects were COPD, bronchiectasis, and ILD-associated obstruction. For the idiopathic forms of those 3 pulmonary diseases (which may have a different underlying pathophysiology than their RA-associated counterparts), autoimmunity and activation of various inflammatory pathways are thought to play an important role. Although still controversial, it has been suggested that COPD represents an autoimmune disease ([22]). T cells generated under cigarette smoke exposure promote the development of an emphysema-like phenotype in mice, and transfer of these T cells into RAG-2–deficient mice could induce this phenotype independent of smoke exposure ([23]).

Similarly, autoantibody and T cell responses to several autoantigens expressed in pulmonary tissue have been described in patients with ILD ([24, 25]). In patients with bronchiectasis, recent findings support a predisposing role for innate immune mechanisms ([26]), and the association with certain HLA class II haplotypes does implicate involvement of the adaptive immune response ([27]).

Considering the similarities between pathogenic mechanisms in these various pulmonary diseases and the pathophysiology of RA, it can be hypothesized that RA-related immune dysfunction may also predispose to abnormal inflammatory responses in extraarticular tissues.

There are some shortcomings to our retrospective study approach. Because of the inherent limitations of a chart review–based diagnosis, it is likely that our estimates do not reflect the full extent of OLD in this population. Tests for the detection of lung disease (including radiographs, CT, and pulmonary function testing) were not systematically used for each patient, and the lack of some information due to time trend effects (e.g., CT became available in the 1970s) may lead to an underestimation of the true incidence.

Additionally, patients with RA have more frequent physician visits than the average patient in the population, and physicians may be more attuned to the possibility of lung disease in RA patients than in healthy people, leading to an overestimation of lung involvement in subjects with RA compared to those without RA (surveillance bias). However, the overall number of chest radiographs and pulmonary function tests that were performed during the followup period was balanced between RA and non-RA subjects.

In summary, we have shown that OLD is more common in patients with RA compared to subjects without RA. Similar to what has been observed with other extraarticular manifestations of RA ([3]), OLD increases the mortality risk of affected patients. When considering recent data on the incidence and mortality of RA-associated ILD ([28]), it becomes apparent that pulmonary disease does represent a major contributor to the overall burden of disease and the risk of premature death in patients with RA. Of note, we cannot exclude that the association of OLD with premature mortality in patients with RA is affected by confounders such as high RA disease activity, use of more potent DMARDs, and associated adverse events or additional extraarticular diseases, which were found to be more common among patients with RA and OLD. However, the high proportion of pulmonary death diagnoses among RA patients with OLD (48%) is pointing toward a causal relationship between obstructive pulmonary disease and premature death in RA patients. Whether patients with RA should be screened for pulmonary disease in a preclinical stage and if detection of subclinical pulmonary pathologies should have any impact on the choice of RA treatment is yet unclear. Future studies will have to clarify how and when OLD in patients with RA should be addressed, and how early effective therapies directed toward joint disease may modify the subsequent risk of developing pulmonary manifestations.


All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Bongartz had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Nannini, Medina-Velasquez, Crowson, Ryu, Vassallo, Gabriel, Matteson, Bongartz.

Acquisition of data. Nannini, Medina-Velasquez, Ryu, Matteson, Bongartz.

Analysis and interpretation of data. Nannini, Medina-Velasquez, Achenbach, Crowson, Ryu, Gabriel, Matteson, Bongartz.